VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 4, 2015) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body's normal immune function in the targeted diseased organ, announced that it has enrolled the first two trial participants into its Phase 2a clinical trial in non-small cell lung cancer.
Qu Biologics' CEO Dr. Hal Gunn commented, "We believe QBKPN SSI represents a promising approach to treating lung cancer by restoring the body's own anti-cancer immune response." He added, "We are very pleased to have enrolled the first two participants in this 10-participant clinical trial. This important trial will provide the basis for a larger randomized controlled clinical trial to assess the effectiveness of QBKPN SSI in the treatment of late stage lung cancer."
The trial is a Phase 2a open label, single-arm, exploratory study to evaluate the safety, tolerability, compliance and mechanism of action of QBKPN site specific immunomodulation (SSI) in subjects with two or more second primary pre-invasive or invasive adenocarcinoma following surgical resection of stage 1 non-small cell lung cancer. The trial is taking place at the BC Cancer Agency Research Centre under Principal Investigator Dr. Stephen Lam. QBKPN SSI is derived from components of inactivated K. pneumoniae bacteria, and is designed to activate an anti-cancer immune response in the lungs.
About Qu Biologics
Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to restore the body's normal immune response. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer and immune-related diseases. The company is currently recruiting participants for a Phase 1/2 placebo-controlled, randomized clinical trial in Crohn's disease and a Phase 2a open-label clinical trial in non-small cell lung cancer.
Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease, Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, and Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth, and recognized expert in immune cell trafficking to tumours. For more information, visit www.qubiologics.com.
About the BC Cancer Agency
The BC Cancer Agency is part of the Provincial Health Services Authority (PHSA), providing province-wide specialty healthcare. Together, we are transforming health care through innovation. The BC Cancer Agency provides a comprehensive cancer control program for the people of British Columbia by working with community partners to deliver a range of oncology services, including prevention, early detection, diagnosis and treatment, research, education, supportive care, rehabilitation and palliative care. For more information, visit www.bccancer.ca.
Qu Biologics Inc. cautions you that statements included in this release that are not a description of historical facts may contain forward-looking statements. These forward-looking statements are only predictions and may involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements. Qu Biologics does not assume any obligation to update any forward-looking statements except as required by law.